Department of Anesthesiology and Intensive Care Unit, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Nord Hospital, Marseille, France.
CHU de Nîmes-Caremeau, Service Réanimation et Surveillance Continue, Pôle ARDU (anesthésie, réanimation, douleur, urgences), 30029, Nîmes cedex, France.
Adv Ther. 2021 May;38(5):2599-2612. doi: 10.1007/s12325-021-01702-0. Epub 2021 Apr 14.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks have led to massive admissions to intensive care units (ICUs). An ultrasound examination of the thorax is widely performed on admission in these patients. The primary objective of our study was to assess the performance of the lung ultrasound score (LUS) on ICU admission to predict the 28-day mortality rate in patients with SARS-CoV-2. The secondary objective was to asses the performance of thoracic ultrasound and biological markers of cardiac injury to predict mortality.
This multicentre, retrospective, observational study was conducted in six ICUs of four university hospitals in France from 15 March to 3 May 2020. Patients admitted to ICUs because of SARS-CoV-2-related acute respiratory failure and those who received an LUS examination at admission were included. The area under the receiver-operating characteristics (ROC) curve was determined for the LUS score to predict the 28-day mortality rate. The same analysis was performed for the Simplified Acute Physiology Score, left ventricular ejection fraction, cardiac output, brain natriuretic peptide and ultra-sensitive troponin levels at admission.
In 57 patients, the 28-day mortality rate was 21%. The area under the ROC curve of the LUS score value on ICU admission was 0.68 [95% CI 0.54-0.82; p = 0.05]. In non-intubated patients on ICU admission (n = 40), the area under the ROC curves was 0.84 [95% CI 0.70-0.97; p = 0.005]. The best cut-off of 22 corresponded to 85% specificity and 83% sensitivity.
LUS scores on ICU admission for SARS-CoV-2 did not efficiently predict the 28-day mortality rate. Performance was better for non-intubated patients at admission. Performance of biological cardiac markers may be equivalent to the LUS score.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 爆发导致大量患者入住重症监护病房 (ICU)。这些患者入院时通常会进行广泛的胸部超声检查。我们的主要研究目的是评估入院时的肺部超声评分 (LUS) 对预测 SARS-CoV-2 患者 28 天死亡率的表现。次要目标是评估胸部超声和心脏损伤的生物标志物对死亡率的预测表现。
这项多中心、回顾性、观察性研究于 2020 年 3 月 15 日至 5 月 3 日在法国的四所大学医院的六个 ICU 进行。纳入因 SARS-CoV-2 相关急性呼吸衰竭而入住 ICU 的患者,以及入院时接受 LUS 检查的患者。确定 LUS 评分预测 28 天死亡率的受试者工作特征 (ROC) 曲线下面积。对入院时简化急性生理学评分、左心室射血分数、心输出量、脑钠肽和超敏肌钙蛋白水平进行了相同的分析。
在 57 例患者中,28 天死亡率为 21%。入院时 LUS 评分的 ROC 曲线下面积为 0.68[95%CI 0.54-0.82;p=0.05]。在入院时未插管的 ICU 患者 (n=40) 中,ROC 曲线下面积为 0.84[95%CI 0.70-0.97;p=0.005]。最佳截断值为 22,对应 85%的特异性和 83%的敏感性。
SARS-CoV-2 患者入院时的 LUS 评分不能有效地预测 28 天死亡率。对于入院时未插管的患者,表现更好。生物心脏标志物的性能可能与 LUS 评分相当。